StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Stock analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

A number of other brokerages have also recently commented on VNRX. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a report on Wednesday, January 8th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Up 1.4 %

Shares of VNRX opened at $0.64 on Wednesday. The firm has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.66. The firm has a market cap of $59.22 million, a PE ratio of -1.77 and a beta of 1.20. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.23.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 358,266 shares of company stock valued at $204,212. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its position in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.